Published June 2019
| Version v1
Journal article
Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial
Creators
- 1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)
- 2. Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)
- 3. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)
Description
For patients with high-risk neuroblastoma (HR-NB), a dose of 21 Gy to the primary tumor site after gross total resection (GTR) provides excellent local control. However, no clinical trial has specifically evaluated the optimal dose of radiation therapy (RT), and RT-related long-term toxicities are of increasing concern. We sought to assess local control, survival outcomes, and toxicity after a reduction in dose to the primary site from 21 Gy to 18 Gy.
Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2019.02.004;
- PII
- S0360301619301944;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 104
- Journal Issue
- 2
- Journal Page Range
- p. 409-414
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 55057200
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CLINICAL TRIALS; HEALTH HAZARDS; NEOPLASMS; PATIENTS; RADIATION DOSES; RADIOTHERAPY; TOXICITY
- Descriptors DEC
- DISEASES; DOSES; HAZARDS; MEDICINE; NUCLEAR MEDICINE; RADIOLOGY; TESTING; THERAPY
Optional Information
- Copyright
- Copyright (c) 2019 Elsevier Inc. All rights reserved.